Higher Pharmacovigilance Advisory Committee

In accordance with the Saudi Food and Drug Authority law issued by Royal decree (م / 6) on 25/1/1425H, and its implemented regulation issued by the authority’s board of directors number 7-7-1428 on 25/7/1429H which include the minister’s decision to create A Higher Pharmacovigilance Advisory Committee. The Committee carries the following tasks:

1. Review and evaluate the safety or benefit/risk review reports of pharmaceutical products referred to the committee.
2. Issuing recommendations and expressing opinions on urgent issues referred to the committee regarding safety and efficacy of pharmaceutical products.
3. Review the implementation of risk minimization measures of pharmaceutical products in the Kingdom of Saudi Arabia and the studies prepared for its evaluation referred to the committee.
4. Review and evaluate of protocols for post authorization safety studies referred to the committee
    

Establish rules and standards governing conflicts of interest with the aim of protecting integrity and combating corruption, and maintaining a healthy environment in all aspects of work and its relationships with stakeholders in general. The conflict of interest is the situation or position in which the objectivity and independence of a governmental employee decision is influenced by a personal, material or moral interest that related to him personally, one of his relatives or close friends; or when the decision in his job is affected by direct or indirect personal considerations or information.

Targeted group:

• SFDA’s Staff
• Members of the committee who are not a SFDA staff
• Part- time consultants
  For more information, you can view the Conflict Interest Rules